BioSpace News Archive

The biotech will supply Canada with fewer doses of its coronavirus vaccine while reaching a financial agreement for the forfeiting of certain doses previously scheduled for delivery.

Johnson & Johnson has licensed Nanobiotix’s lead radioenhancer candidate, designed to increase the efficacy of radiation treatment in cancers, capitalizing on the latter’s rocky financial situation.

After its Biologics License Application was rejected by the FDA, BrainStorm’s Phase III data suggest its amyotrophic lateral sclerosis candidate significantly lowers neurofilament light chain levels.

The biotech Monday announced a clinical hold on its HEMO-CAR-T candidate, which is being trialed for the treatment of acute myeloid leukemia, due to manufacturing concerns cited by the regulator.

The biotech has acquired an exclusive global license for Shanghai-based DualityBio’s investigational antibody-drug conjugate for select solid tumors.

Broncus Holding Corporation has completed the first case of registered clinical trials of its targeted lung denervation radiofrequency ablation system.

Biophytis SA announced that it has filed for approval on the Food and Drug Administration portal to launch its SARA-31 program in the U.S., the first ever Phase 3 study in sarcopenia.

Nicox SA provided details of a U.S. market survey evaluating the commercial potential of NCX 470, a nitric oxide -donating bimatoprost, in development for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension and estimated potential global annual net sales for NCX 470.

Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announced that it has submitted a first Clinical Trial Application for OTOF-GT to the UK’s Medicines and Healthcare products Regulatory Agency.

NANOBIOTIX announced a global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for the investigational, potential first-in-class radioenhancer NBTXR3.